(866) 389-4659

StemCyte, Inc. has delivered more than 2,300 cord blood transplants to over 325 transplant centers across 40 countries since 1997, one of the highest clinical track records among cord blood banks. StemCyte's cord blood units have been used in transplants for leukemia, sickle cell disease, primary immunodeficiency, and inherited metabolic disorders, and the company contributed cord blood to the first reported HIV cure achieved via cord blood transplantation (the New York Patient, published in Cell, 2023). StemCyte is FACT and AABB accredited and holds FDA US License 2280 for REGENECYTE®.

Track Record

The global standard in cord blood banking

2,300+ cord blood units to 325+ medical centers across 40 countries. The highest documented private-bank record.

The standard

What standards does StemCyte meet?

Licensed

REGENECYTE® FDA-Licensed

Our cord blood product REGENECYTE® earned an FDA BLA, the same rigorous approval pathway required for vaccines, blood products, and gene therapies.

Most banksREGENECYTE®
Other private banks are merely registered with the FDA. StemCyte's product is licensed.
FACT
Accredited since 2006

Foundation for the Accreditation of Cellular Therapy. The gold standard for cell therapy laboratories.

AABB
Accredited since 2002

American Association of Blood Banks. Premier accreditation for blood banking.

cGMP
Compliant

Current Good Manufacturing Practices. Same standards required for pharmaceuticals.

The track record
2,300+
transplants shipped to hospitals worldwide

More clinical transplants than any other private cord blood bank. Our units have been used in life-saving treatments across six continents.

325+ Hospitals
40 Countries
29 Years
The frontier

What cord blood makes possible

StemCyte cord blood units aren't just stored. They're advancing the frontier of medicine.

Landmark

Toward an HIV Cure

Undetectable was never the finish line.

A StemCyte-screened cord blood unit contributed to the first possible HIV cure in a woman, using an approach that could reach patients adult donors never could.

Hsu et al., Cell 2023 · IMPAACT P1107
Read the full story
Emerging

Investigational therapies

StemCyte sponsors clinical trials exploring cord blood for Long COVID and ischemic stroke, with REGENECYTE® receiving FDA RMAT designation.

3 StemCyte-sponsored clinical trials
Visit StemCyte Biologics
The protection

The only private bank with public bank access

StemCyte operates both a private and public cord blood bank. When you add Public Bank Access, your family gets access to donor stem cells if your child ever needs more than their stored unit. It's a safety net no other private bank can offer.

Learn about PBA
Our global partners

Which transplant centers use StemCyte units?

StemCyte cord blood units have been used at leading institutions across 40 countries.

United States
Cedars-SinaiLos Angeles, CA
Children’s Hospital Los AngelesLos Angeles, CA
Children’s Hospital of PhiladelphiaPhiladelphia, PA
City of HopeDuarte, CA
Cleveland ClinicCleveland, OH
Dana-Farber Cancer InstituteBoston, MA
Duke University Medical CenterDurham, NC
Johns HopkinsBaltimore, MD
Massachusetts General HospitalBoston, MA
Mayo ClinicRochester, MN
MD Anderson Cancer CenterHouston, TX
Memorial Sloan KetteringNew York, NY
St. Jude Children’s Research HospitalMemphis, TN
Stanford Health CareStanford, CA
Texas Children’s HospitalHouston, TX
UCLA Medical CenterLos Angeles, CA
Global
Apollo Specialty HospitalChennai, India
Chang Gung Children’s HospitalTaiwan
Foothills Medical CenterCalgary, Canada
Great Ormond Street HospitalLondon, UK
Hôpital Saint LouisParis, France
Karolinska University HospitalStockholm, Sweden
National University HospitalSingapore
Prince of Wales HospitalSydney, Australia
RigshospitaletCopenhagen, Denmark
The Hospital for Sick ChildrenToronto, Canada

The numbers tell the full story.

See how StemCyte's 2,300+ transplants and FDA-licensed REGENECYTE® product stack up against CBR, ViaCord, and Cryo-Cell.

View the comparison